Loading...

We've got a brand new version of Simply Wall St! Try it out

Grown Rogue International

CNSX:GRIN
Snowflake Description

Worrying balance sheet with weak fundamentals.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
GRIN
CNSX
CA$15M
Market Cap
  1. Home
  2. CA
  3. Pharmaceuticals & Biotech
Company description

Grown Rogue International Inc., a vertically-integrated cannabis company, cultivates, produces, and sells cannabis products in Oregon. The last earnings update was 80 days ago. More info.


Add to Portfolio Compare Print
GRIN Share Price and Events
7 Day Returns
20.6%
CNSX:GRIN
-0.2%
CA Pharmaceuticals
1.2%
CA Market
1 Year Returns
-
CNSX:GRIN
-45.8%
CA Pharmaceuticals
-0.4%
CA Market
GRIN Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Grown Rogue International (GRIN) 20.6% 24.2% -14.6% - - -
CA Pharmaceuticals -0.2% -1.8% -21.5% -45.8% 251% 334.4%
CA Market 1.2% 3.3% 0.8% -0.4% 7.4% 4.5%
1 Year Return vs Industry and Market
  • No trading data on GRIN.
  • No trading data on GRIN.
Price Volatility
Industry
5yr Volatility vs Market

Value

 Is Grown Rogue International undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Grown Rogue International. This is due to cash flow or dividend data being unavailable. The share price is CA$0.205.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Grown Rogue International's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Grown Rogue International's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
CNSX:GRIN PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-04-30) in USD $-0.16
CNSX:GRIN Share Price ** CNSX (2019-09-19) in CAD CA$0.21
CNSX:GRIN Share Price converted to USD reporting currency Exchange rate (CAD/ USD) 0.754 $0.15
Canada Pharmaceuticals Industry PE Ratio Median Figure of 13 Publicly-Listed Pharmaceuticals Companies 18.72x
Canada Market PE Ratio Median Figure of 540 Publicly-Listed Companies 14.11x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Grown Rogue International.

CNSX:GRIN PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= CNSX:GRIN Share Price ÷ EPS (both in USD)

= 0.15 ÷ -0.16

-0.98x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Grown Rogue International is loss making, we can't compare its value to the CA Pharmaceuticals industry average.
  • Grown Rogue International is loss making, we can't compare the value of its earnings to the Canada market.
Price based on expected Growth
Does Grown Rogue International's expected growth come at a high price?
Raw Data
CNSX:GRIN PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -0.98x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
Canada Pharmaceuticals Industry PEG Ratio Median Figure of 7 Publicly-Listed Pharmaceuticals Companies 1.57x
Canada Market PEG Ratio Median Figure of 246 Publicly-Listed Companies 0.95x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Grown Rogue International, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Grown Rogue International's assets?
Raw Data
CNSX:GRIN PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-04-30) in USD $0.03
CNSX:GRIN Share Price * CNSX (2019-09-19) in CAD CA$0.21
CNSX:GRIN Share Price converted to USD reporting currency Exchange rate (CAD/ USD) 0.754 $0.15
Canada Pharmaceuticals Industry PB Ratio Median Figure of 151 Publicly-Listed Pharmaceuticals Companies 2.32x
Canada Market PB Ratio Median Figure of 2,454 Publicly-Listed Companies 1.44x
CNSX:GRIN PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= CNSX:GRIN Share Price ÷ Book Value per Share (both in USD)

= 0.15 ÷ 0.03

5.28x

* Primary Listing of Grown Rogue International.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Grown Rogue International is overvalued based on assets compared to the CA Pharmaceuticals industry average.
X
Value checks
We assess Grown Rogue International's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. Grown Rogue International has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Grown Rogue International expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Grown Rogue International has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
110.6%
Expected Pharmaceuticals industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Grown Rogue International expected to grow at an attractive rate?
  • Unable to compare Grown Rogue International's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Grown Rogue International's earnings growth to the Canada market average as no estimate data is available.
  • Unable to compare Grown Rogue International's revenue growth to the Canada market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
CNSX:GRIN Future Growth Rates Data Sources
Data Point Source Value (per year)
Canada Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 110.6%
Canada Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 58.6%
Canada Market Earnings Growth Rate Market Cap Weighted Average 12.8%
Canada Market Revenue Growth Rate Market Cap Weighted Average 5.9%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
CNSX:GRIN Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
CNSX:GRIN Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
CNSX:GRIN Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-04-30 4 -3 -11
2019-01-31 3 -4 -11
2018-10-31 2 -2 -8
2018-07-31 1 -3 -5
2017-10-31 0 -1 0

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Grown Rogue International is high growth as no earnings estimate data is available.
  • Unable to determine if Grown Rogue International is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
CNSX:GRIN Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Grown Rogue International Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

CNSX:GRIN Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
CNSX:GRIN Past Financials Data
Date (Data in USD Millions) EPS *
2019-04-30 -0.16
2019-01-31 -0.15
2018-10-31 -712.18
2018-07-31
2017-10-31

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Grown Rogue International will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Grown Rogue International's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Pharmaceuticals & Biotech companies here
  2. Grown Rogue International's competitive advantages and company strategy can generally be found in its financial reports archived here.
  3. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess Grown Rogue International's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Canada market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Canada market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Grown Rogue International has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Grown Rogue International performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Grown Rogue International's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Grown Rogue International does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.
  • Unable to compare Grown Rogue International's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Grown Rogue International's 1-year growth to the CA Pharmaceuticals industry average as it is not currently profitable.
Earnings and Revenue History
Grown Rogue International's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Grown Rogue International Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

CNSX:GRIN Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-04-30 4.19 -11.47 5.00
2019-01-31 2.60 -10.97 4.13
2018-10-31 1.93 -7.51 3.75
2018-07-31 1.29 -4.90 3.50
2017-10-31 0.16 -0.30 1.05

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Grown Rogue International has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Grown Rogue International has efficiently used its assets last year compared to the CA Pharmaceuticals industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Grown Rogue International improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Grown Rogue International's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Grown Rogue International has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Grown Rogue International's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Grown Rogue International's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Grown Rogue International's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
  • Grown Rogue International's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Grown Rogue International's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is covered by short term assets, assets are 1.7x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Grown Rogue International Company Filings, last reported 4 months ago.

CNSX:GRIN Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-04-30 2.12 1.05 0.32
2019-01-31 3.47 1.05 0.53
2018-10-31 -0.25 2.28 0.83
2018-07-31 -0.27 2.06 0.10
2017-10-31 -0.30 1.95 0.45
  • Grown Rogue International's level of debt (49.6%) compared to net worth is high (greater than 40%).
  • Unable to establish if Grown Rogue International's debt level has increased without past 5-year debt data.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Grown Rogue International has less than a year of cash runway based on current free cash flow.
  • Grown Rogue International has less than a year of cash runway if free cash flow continues to grow at historical rates of 44% each year.
X
Financial health checks
We assess Grown Rogue International's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Grown Rogue International has a total score of 1/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Grown Rogue International's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Grown Rogue International dividends.
If you bought CA$2,000 of Grown Rogue International shares you are expected to receive CA$0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Grown Rogue International's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Grown Rogue International's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
CNSX:GRIN Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
North America Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 10 Stocks 2.8%
Canada Market Average Dividend Yield Market Cap Weighted Average of 334 Stocks 3.5%
Canada Minimum Threshold Dividend Yield 10th Percentile 1.2%
Canada Bottom 25% Dividend Yield 25th Percentile 2%
Canada Top 25% Dividend Yield 75th Percentile 5.8%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

CNSX:GRIN Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Grown Rogue International has not reported any payouts.
  • Unable to verify if Grown Rogue International's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Grown Rogue International's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Grown Rogue International has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Grown Rogue International's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.2%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Grown Rogue International afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Grown Rogue International has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Grown Rogue International's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
J. Strickler
AGE 39
TENURE AS CEO 0.8 years
CEO Bio

Mr. J. Obie Strickler serves as President, Chief Executive Officer and Chairman at Grown Rogue International Inc. He is also CEO, President, and founder of GRUS. He founded Canopy Management, LLC in 2015 to consolidate the three medical facilities he had operated since 2006 within one company. Mr. Strickler formed GRUS in 2016 and entered the Oregon recreational cannabis market with a plan to build a multi-national cannabis brand. Mr. Strickler has been active in the Oregon medical marijuana market since early 2000 where he organically scaled a single 15 plant property to four separate facilities with approximately 200 outdoor plants and 30 lights operating indoors. During the time he was financing and overseeing Canopy’s growth he was also the regional manager for a large multi-service environmental company where he oversaw a staff of 15 people before starting his own business in 2011 to provide management services to large natural resource companies primarily in the mining sector. In this role, he was responsible for building and integrating complex technical teams to advance large, world-class, multi-billion-dollar mining projects from exploration through feasibility primarily in base and precious metals. In 2014, Mr. Strickler teamed with aerospace engineers to form HyperSciences, Inc a platform technology company focused on commercializing hypervelocity technology into a variety of industrial applications. Mr. Strickler helped secure a large contract with one of the world’s larger oil and gas providers to solve deep drilling challenges and moved this project through proof of concept before departing to focus on the opportunities in cannabis full time. Mr. Strickler will take his production experience in the cannabis industry and his integration and execution experience from the natural resource industry to build GRUS into a premier cannabis company. Mr. Strickler has a BS in Geology from Southern Oregon University and is also an Oregon Professional Geologist.

CEO Compensation
  • Insufficient data for J. to compare compensation growth.
  • Insufficient data for J. to establish whether their remuneration is reasonable compared to companies of similar size in Canada.
Management Team Tenure

Average tenure and age of the Grown Rogue International management team in years:

0.8
Average Tenure
39
Average Age
  • The average tenure for the Grown Rogue International management team is less than 2 years, this suggests a new team.
Management Team

J. Strickler

TITLE
President
AGE
39
TENURE
0.8 yrs

Mike Johnston

TITLE
CFO & Corporate Secretary
AGE
37
TENURE
0.8 yrs

Rob Rigg

TITLE
Executive Director of Operations & VP of Marketing

Buddy Wilson

TITLE
Vice President of Sales

Jacques Habra

TITLE
Chief Strategy Officer
AGE
44
TENURE
0.8 yrs
Board of Directors Tenure

Average tenure and age of the Grown Rogue International board of directors in years:

0.8
Average Tenure
39
Average Age
  • The average tenure for the Grown Rogue International board of directors is less than 3 years, this suggests a new board.
Board of Directors

J. Strickler

TITLE
President
AGE
39
TENURE
0.8 yrs

Steven Gledhill

TITLE
Director
AGE
58
TENURE
0.8 yrs

Abhilash Patel

TITLE
Director
AGE
38
TENURE
0.8 yrs
Who owns this company?
Recent Insider Trading
  • Grown Rogue International individual insiders have sold more shares than they have bought in the past 3 months, but not in substantial volumes.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (CA$) Value (CA$)
12. Sep 19 Buy J. Strickler Individual 12. Sep 19 12. Sep 19 18,500 CA$0.17 CA$3,055
22. Aug 19 Sell Stephen Gledhill Individual 20. Aug 19 21. Aug 19 -100,000 CA$0.16 CA$-15,552
09. Aug 19 Buy J. Strickler Individual 31. Jul 19 31. Jul 19 3,000 CA$0.23 CA$690
31. Jul 19 Buy J. Strickler Individual 26. Jul 19 26. Jul 19 4,000 CA$0.25 CA$1,000
19. Jul 19 Buy J. Strickler Individual 18. Jul 19 18. Jul 19 12,000 CA$0.17 CA$1,930
05. Jul 19 Buy J. Strickler Individual 04. Jul 19 05. Jul 19 20,000 CA$0.23 CA$4,328
12. Jun 19 Buy J. Strickler Individual 11. Jun 19 11. Jun 19 25,000 CA$0.24 CA$6,000
12. Apr 19 Sell Jacques Habra Individual 10. Apr 19 11. Apr 19 -11,500 CA$0.42 CA$-4,838
21. Mar 19 Sell Jacques Habra Individual 15. Mar 19 15. Mar 19 -40,000 CA$0.32 CA$-12,800
21. Mar 19 Sell Abhilash Patel Individual 19. Mar 19 19. Mar 19 -50,000 CA$0.41 CA$-20,425
26. Feb 19 Sell Abhilash Patel Individual 25. Feb 19 25. Feb 19 -50,000 CA$0.28 CA$-14,000
16. Feb 19 Sell Abhilash Patel Individual 14. Feb 19 14. Feb 19 -43,000 CA$0.24 CA$-10,320
23. Jan 19 Sell Abhilash Patel Individual 22. Jan 19 22. Jan 19 -52,000 CA$0.28 CA$-14,560
22. Jan 19 Sell Abhilash Patel Individual 17. Jan 19 18. Jan 19 -24,500 CA$0.31 CA$-7,347
16. Jan 19 Sell Abhilash Patel Individual 14. Jan 19 15. Jan 19 -56,500 CA$0.34 CA$-17,845
15. Jan 19 Sell Abhilash Patel Individual 14. Jan 19 14. Jan 19 -9,000 CA$0.32 CA$-2,805
14. Jan 19 Sell Abhilash Patel Individual 10. Jan 19 11. Jan 19 -59,000 CA$0.34 CA$-19,168
11. Jan 19 Sell Jacques Habra Individual 07. Jan 19 08. Jan 19 -7,500 CA$0.35 CA$-2,624
X
Management checks
We assess Grown Rogue International's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Grown Rogue International has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

How Much Of Grown Rogue International Inc. (CNSX:GRIN) Do Insiders Own?

Grown Rogue International is a smaller company with a market capitalization of CA$17m, so it may still be flying under the radar of many institutional investors. … See our latest analysis for Grown Rogue International CNSX:GRIN Ownership Summary, August 7th 2019 What Does The Lack Of Institutional Ownership Tell Us About Grown Rogue International? … Insider Ownership Of Grown Rogue International The definition of company insiders can be subjective, and does vary between jurisdictions.

Simply Wall St -

Company Info

Description

Grown Rogue International Inc., a vertically-integrated cannabis company, cultivates, produces, and sells cannabis products in Oregon. Its products include flower products, such as indicas, sativas, and hybrids; pre-rolls; vape cartridges; concentrates and oils; dark chocolate line; and other derivative products. The company sells its products directly to dispensaries. The company is based in Toronto, Canada.

Details
Name: Grown Rogue International Inc.
GRIN
Exchange: CNSX
Founded:
CA$14,855,512
72,465,916
Website: http://www.grownrogue.com
Address: Grown Rogue International Inc.
340 Richmond Street West,
Toronto,
Ontario, M5V 1X2,
Canada
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
CNSX GRIN Common Shares Canadian National Stock Exchange CA CAD 16. Nov 2018
Number of employees
Current staff
Staff numbers
0
Grown Rogue International employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/09/20 01:33
End of day share price update: 2019/09/19 00:00
Last estimates confirmation: 2019/02/13
Last earnings filing: 2019/07/02
Last earnings reported: 2019/04/30
Last annual earnings reported: 2018/10/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.